US4579840A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of blocking immune complex binding to immunoglobulin Fc receptors
Assignee: Immunetech Pharmaceuticals
•
Filing: 1983-08-12
•
Granted: 1986-04-01
•
Expires: 2003-08-12
Abstract
Abstract Methods and peptides for blocking immunogloblin Fc receptors are set forth.
Inventors
- 👤 Gary S. Hahn
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-01 07:07
CPC Classifications
C; C07; C07K; C07K5/00; C07K5/04; C07K5/10; C07K5/1021; C07K16/00; C07K16/06; C07K16/065; A; A61; A61K; A61K38/00; Y; Y10; Y10S; Y10S530/00; Y10S530/861; Y10S530/866; Y10S530/868
Claims Analysis
Total Claims: 6
Claim 1
Independent Claim
201 words
A method of blocking immune complex binding to immunoglobulin Fc receptors, comprising administering an effective amount to modulate immune complex mediated immunosuppression of at least one peptide having an amino acid sequence selected from the group consisting of: ______________________________________
A--B--C--D--E--F--G--H--I--J--K--L--M--N,
A--B--C--D--E--F--G--H--I--J--K--L--M,
A--B--C--D--E--F--G--H--I--J--K--L,
A--B--C--D--E--F--G--H--I--J--K,
A--B--C--D--E--F--G--H--I--J,
A--B--C--D--E--F--G--H--I,
A--B--C--D--E--F--G--H,
A--B--C--D--E--F--G,
A--B--C--D--E--F,
A--B--C--D--E,
A--B--C--D,
B--C--D--E--F--G--H--I--J--K--L--M--N,
B--C--D--E--F--G--H--I--J--K--L--M,
B--C--D--E--F--G--H--I--J--K--L,
B--C--D--E--F--G--H--I--J--K,
B--C--D--E--F--G--H--I--J,
B--C--D--E--F--G--H--I,
B--C--D--E--F--G--H,
B--C--D--E--F--G,
B--C--D--E--F,
B--C--D--E,
C-- D--E--F--G--H--I--J--K--L--M--N,
C--D--E--F--G--H--I--J--K--L--M,
C--D--E--F--G--H--I--J--K--L,
C--D--E--F--G--H--I--J--K,
C--D--E--F--G--H--I--J,
C--D--E--F--G--H--I,
C--D--E--F--G--H,
C--D--E--F--G,
C--D--E--F,
D--E--F--G--H--I--J--K--L--M--N,
D--E--F--G--H--I--J--K--L--M,
D--E--F--G--H--I--J--K--L,
D--E--F--G--H--I--J--K,
D--E--F--G--H--I--J,
D--E--F--G--H--I,
D--E--F--G--H,
D--E--F--G,
E--F--G--H--I--J--K--L--M--N,
E--F--G--H--I--J--K--L--M,
E--F--G--H--I--J--K--L,
E--F--G--H--I--J--K,
E--F--G--H--I--J,
E--F--G--H--I,
E-- F--G--H,
F--G--H--I--J--K--L--M--N,
F--G--H--I--J--K--L--M,
F--G--H--I--J--K--L,
F--G--H--I--J--K,
F--G--H--I--J,
F--G--H--I,
G--H--I--J--K--L--M--N,
G--H--I--J--K--L--M,
G--H--I--J--K--L,
G--H--I--J--K,
G--H--I--J,
H--I--J--K--L--M--N,
H--I--J--K--L--M,
H--I--J--K--L,
H--I--J--K,
I--J--K--L--M--N,
I--J--K--L--M,
I--J--K--L,
J--K--L--M--N,
J--K--L--M, and
K--L--M--N
______________________________________ wherein A is Thr, Ser, or Ala; B is Val, Leu, Ile, or Ala; C is Leu, Val, Ile, or Ala; D is His; E is Gln, Asn, Glu, or Asp; F is Asn, Gln, Asp, or Glu; G is Trp, Tyr, Phe, Ala, Val, Leu, or Ile; H is Leu, Val, Ala, or Ile; I is Asp, or Glu; J is Gly, or Ala; K is Lys, Arg, or Orn; L is Glu, or Asp; M is Tyr; and N is Val, Leu, Ile, or Ala and pharmaceutically acceptable salts thereof.
Claim 2
Independent Claim
201 words
A method of blocking immune complex binding to immunoglobulin Fc receptors, comprising administering an effective amount to modulate immune complex mediated immunosuppression of at least one peptide having an amino acid sequence selected from the group consisting of: ______________________________________
A--B--C--D--E--F--G--H--I--J--K--L--M--N,
A--B--C--D--E--F--G--H--I--J--K--L--M,
A--B--C--D--E--F--G--H--I--J--K--L,
A--B--C--D--E--F--G--H--I--J--K,
A--B--C--D--E--F--G--H--I--J,
A--B--C--D--E--F--G--H--I,
A--B--C--D--E--F--G--H,
A--B--C--D--E--F--G,
A--B--C--D--E--F,
A--B--C--D--E,
A--B--C--D,
B--C--D--E--F--G--H--I--J--K--L--M--N,
B--C--D--E--F--G--H--I--J--K--L--M,
B--C--D--E--F--G--H--I--J--K--L,
B--C--D--E--F--G--H--I--J--K,
B--C--D--E--F--G--H--I--J,
B--C--D--E--F--G--H--I,
B--C--D--E--F--G--H,
B--C--D--E--F--G,
B--C--D--E--F,
B--C--D--E,
C-- D--E--F--G--H--I--J--K--L--M--N,
C--D--E--F--G--H--I--J--K--L--M,
C--D--E--F--G--H--I--J--K--L,
C--D--E--F--G--H--I--J--K,
C--D--E--F--G--H--I--J,
C--D--E--F--G--H--I,
C--D--E--F--G--H,
C--D--E--F--G,
C--D--E--F,
D--E--F--G--H--I--J--K--L--M--N,
D--E--F--G--H--I--J--K--L--M,
D--E--F--G--H--I--J--K--L,
D--E--F--G--H--I--J--K,
D--E--F--G--H--I--J,
D--E--F--G--H--I,
D--E--F--G--H,
D--E--F--G,
E--F--G--H--I--J--K--L--M--N,
E--F--G--H--I--J--K--L--M,
E--F--G--H--I--J--K--L,
E--F--G--H--I--J--K,
E--F--G--H--I--J,
E--F--G--H--I,
E-- F--G--H,
F--G--H--I--J--K--L--M--N,
F--G--H--I--J--K--L--M,
F--G--H--I--J--K--L,
F--G--H--I--J--K,
F--G--H--I--J,
F--G--H--I,
G--H--I--J--K--L--M--N,
G--H--I--J--K--L--M,
G--H--I--J--K--L,
G--H--I--J--K,
G--H--I--J,
H--I--J--K--L--M--N,
H--I--J--K--L--M,
H--I--J--K--L,
H--I--J--K,
I--J--K--L--M--N,
I--J--K--L--M,
I--J--K--L,
J--K--L--M--N,
J--K--L--M, and
K--L--M--N
______________________________________ wherein A is Thr, Ser, or Ala; B is Val, Leu, Ile, or Ala; C is Leu, Val, Ile, or Ala; D is His; E is Gln, Asn, Glu, or Asp; F is Asn, Gln, Asp, or Glu; G is Trp, Tyr, Phe, Ala, Val, Leu, or Ile; H is Leu, Val, Ala, or Ile; I is Asp, or Glu; J is Gly, or Ala; K is Lys, Arg, or Orn; L is Glu, or Asp; M is Tyr; and N is Val, Leu, Ile, or Ala and pharmaceutically acceptable salts thereof.
Claim 3
Dependent Claim
38 words
The method of blocking immune complex binding to immunoglobulin Fc receptors as set forth in claim 1, comprising administering an effective amount of at least one of said peptides to reduce immune complex mediated inflammation or tissue destruction.
Claim 4
Dependent Claim
35 words
The method of blocking immune complex binding to immunloglobulin Fc receptors as set forth in claim 1, comprising administering an effective amount of at least one of said peptides to reduce the human allergic response.
Claim 5
Dependent Claim
40 words
The method of blocking immune complex binding to immunoglobulin Fc receptors as set forth in claim 1, comprising administering an effective amount of at least one of said peptides to stimulate the synthesis of immunoglobulins in response to an antigen.
Claim 6
Dependent Claim
40 words
The method of blocking immune complex binding to immunoglobulin Fc receptors as set forth in claim 1, comprising administering an effective amount of at least one of said peptides to inhibit the synthesis of immunoglobulins in response to an antigen.
References Cited (Backward Citations)
US3928306A
Cited
US3971736A
Cited
US4161522A
Cited
US4171299A
Cited
US4107298A
Cited
US4438029A
Cited
US4426324A
Cited
US4250086A
Cited
US4309340A
Cited
US4369137A
Cited
US4341761A
Cited
US4311639A
Cited
US4310456A
Cited
US4308181A
Cited
US4353822A
Cited
US4428938A
Cited
US4392997A
Cited
US4374765A
Cited
US4377516A
Cited
US4415493A
Cited
US4395404A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1989-03-31 | 1989-09-30 | 1990-04-01 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1993-03-31 | 1993-09-30 | 1994-04-01 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1997-03-31 | 1997-09-30 | 1998-04-01 | $7700.00 | Window Closed / Lapsed |